Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Testicular Cancer: early-phase trial registry
8 of 12 indexed Testicular Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 8 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Testicular Cancer: 12 US clinical trials tracked, 8 recruiting.
Testicular Cancer is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Indiana University, running 2 of these trials.
Enrollment posture brief
Registry condition testicular-cancer
OPEN 8 | RECR 67% | LATE 1 | EARLY 5 | RANK #1429 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Testicular Cancer lists 8 open slots (67% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Testicular Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Testicular Cancer is recruiting above its size-band peers.
8 of 12 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Testicular Cancer research.
Indiana University accounts for 2 of 12 trials (16.7%). 11 distinct sponsors appear on at least one study for this condition label.
-
Most Testicular Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 70 among the 12 trials that report a genuine target (sentinel values excluded). 9 of those (75%) plan for fewer than 100 participants.
-
Testicular Cancer research is mostly interventional.
11 interventional and 1 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
Duke University
NCT06371768
A Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Testicular Cancer Survivors
University of California, Irvine
NCT05836688
Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection.
Indiana University
NCT06593665
Patient Reported Experiences With Sparing External Oblique Fascia Vs Standard Inguinal Orchiectomy
Loma Linda University
NCT06828185
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Context Therapeutics
NCT06515613
A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy
Wake Forest University Health Sciences
NCT06866964
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
University of Arizona
NCT06814496
A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest
Dana-Farber Cancer Institute
NCT05899361
Pursuing Exploration Into the Supportive Care Needs and Intervention Preferences of Survivors of Testicular Cancer
Indiana University
NCT07228637
High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors
M.D. Anderson Cancer Center
NCT00936936
Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
Nasser Hanna
NCT02429466
Role of Axumin PET Scan in Germ Cell Tumor
University of Texas Southwestern Medical Center
NCT03426865
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Testicular Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Testicular Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Testicular Cancer page
12 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Testicular Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Indiana University sponsors the most Testicular Cancer trials on record, review their full trial history before evaluating a specific study. See Indiana University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Testicular Cancer condition card totals 12 registered trials; most-linked intervention Guadecitabine (SGI-110); top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.